Back to News
Feb 23, 2026 12:01 PM

Novo Nordisk's Loss Is Eli Lilly's Gain

Eli Lilly and Company (NYSE:LLY) shares are up on Monday as the company benefits from positive market sentiment following Novo Nordisk A/S’ (NYSE:NVO) disappointing trial results for a weight-loss drug, adding pressure as broader markets edged lower.

Eli Lilly Gains as Novo Nordisk Trial Setback

Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.

The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.

The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema ...